When an antiemetic becomes an analgesic: robust evidence for a clinical use still far too uncommon in Italy

If I told you that in your medication cabinet you already have an effective analgesic for migraine, with an NNT of 2-3 and demonstrated superiority over placebo, you would probably think of NSAIDs or triptans. Instead, I'm talking about metoclopramide - yes, the very one you routinely use for nausea.

In Italy, the use of metoclopramide for the direct treatment of migraine is still surprisingly limited, despite decades of solid scientific evidence supporting its efficacy. It's time to rediscover this "old" drug in a new clinical light.

🔬 The pharmacological rationale: more than meets the eye

Metoclopramide is not effective in migraine by chance or only as a "side effect" of its antiemetic action. Its mechanism of action involves neurochemical pathways directly implicated in migraine pathophysiology.

As a central D₂ dopaminergic receptor antagonist, metoclopramide acts at the level of the area postrema and the trigeminovascular system, interrupting the neuroinflammatory cascade typical of migraine attacks.

But there's more: the drug also presents activity on serotonergic receptors - it acts as:

• 5-HT₃ antagonist
• 
  
• 5-HT₄ agonist
• 
  
  Modulating pain transmission systems through mechanisms independent of its gastrokinetic action.
  
  This dual activity explains why metoclopramide is particularly effective in migraine attacks characterized by predominant nausea, but also why it maintains analgesic efficacy independently of the presence of gastrointestinal symptoms.
  
  

  📚 The scientific evidence: 35 years of convincing data

  
  
  

  The pioneering studies

  
  
  The efficacy of metoclopramide in migraine is not a recent discovery. As early as 1990, Tek and colleagues published in Annals of Emergency Medicine a randomized, controlled, double-blind study that demonstrated impressive results:
  
  

• 67% of patients treated with metoclopramide 10 mg IV obtained effective relief within one hour
• 
  
• Only 19% of the placebo group showed improvement (p<0.001)
• 
  
• A Number Needed to Treat of 2-3 that would be the envy of many modern analgesics
• 
  
  

  Modern confirmations

  
  
  Meta-analyses in recent years have consolidated this evidence. A 2023 systematic review of 16 studies and 1,934 patients confirmed the efficacy of metoclopramide in reducing the intensity of acute headaches, with sustained benefits up to 24 hours after administration.
  
  Particularly interesting is how modern meta-analyses consistently confirm the superiority of metoclopramide over placebo, with a generally favorable tolerability profile compared to other agents used in acute migraine.
  
  

  Recognition by guidelines

  
  
  International guidelines have progressively recognized the value of metoclopramide: the American Headache Society recommends it as second-line therapy for acute migraine, particularly in the presence of significant nausea.
  
  However, in Italy this recommendation has not yet found adequate clinical dissemination.
  
  

  📊 The study that changes the perspective: Barbera 2025

  
  
  The recent study by Barbera and colleagues, published in Journal of Emergency Medicine, adds an important piece to this puzzle by highlighting not only the efficacy of metoclopramide, but also the operational advantages of the intramuscular route.
  
  

  The striking numbers

  
  
  In this retrospective study of:
  

• 1,445 total visits
• 
  
• 522 included in the propensity-matched analysis (261 + 261) with acute headaches
• 
  
  The researchers compared metoclopramide 10 mg intramuscularly versus intravenously. The results show:
  
  
• Significantly reduced Emergency Department length of stay: 67 minutes (median) for the IM route versus 168 minutes for the IV route
• 
  
• Equivalent analgesic efficacy
• 
  
  

  The practical implication

  
  
  This study suggests that not only does metoclopramide work for migraine, but the intramuscular route can be just as effective as the intravenous route, with the additional advantage of significantly accelerating Emergency Department flow.
  
  For patients with "clear" migraine - young, with known history, typical symptoms - the IM route eliminates the need for immediate venous access.
  
  

  🤔 A necessary critical reflection

  
  
  Before radically modifying our clinical practice, it is important to consider some methodological aspects of the Barbera study.
  
  

  Limitations to keep in mind

  
  
  

• The retrospective design does not allow definitive causal relationships to be established
• 
  
• The lack of information on diagnostic workup performed in the two groups represents a significant gap
• 
  
• The sample imbalance (only 10% IM vs 90% IV) suggests that clinicians intuitively selected different patients for the two routes
• 
  
  It is possible that the IM route was reserved for cases of "clear migraine" while the IV route for "undifferentiated headaches" that required more investigations.
  
  

  💡 Implications for Italian clinical practice

  
  
  

  A necessary paradigm shift

  
  
  The available evidence should encourage Italian clinicians to consider metoclopramide as first choice for acute migraine, especially in the presence of nausea. The standard dose of 10 mg (IV or IM) has demonstrated consistent efficacy and a favorable safety profile.
  
  

  Practical indications

  
  
  For typical migraines with nausea: Metoclopramide 10 mg IM may be the optimal choice, avoiding venous access
  
  For headaches requiring workup: The IV route remains appropriate if vascular access needs to be maintained
  
  Prevention of side effects: Consider premedication with diphenhydramine in patients with a history of extrapyramidal reactions
  
  

  Systemic advantages

  
  
  The adoption of IM metoclopramide for selected migraines could:
  
  

• Significantly reduce ED length of stay
• 
  
• Improve patient satisfaction
• 
  
• Optimize the allocation of nursing resources
• 
  
• Facilitate flow management during peak influx periods

🎯 The final message

Metoclopramide for migraine is not an experimental novelty, but an evidence-based therapy that deserves greater consideration in Italian clinical practice. The Barbera study reminds us that, in addition to the already demonstrated efficacy, the intramuscular route can offer significant operational advantages.

It is not about revolutionizing existing protocols, but about intelligently integrating an underutilized therapeutic option into our clinical armamentarium. In an era where efficiency and quality must go hand in hand, metoclopramide represents a perfect example of how "old" drugs can still teach us new strategies.

The next time you see a patient arrive with typical migraine, remember: the solution might be simpler - and closer - than you think.

---

References

1. Barbera AR, Gould LA, Wills WB, et al. Examining the Effect of Intramuscular versus Intravenous Metoclopramide for Treatment of Acute Headaches to Expedite Throughput in the Emergency Department. J Emerg Med. 2025;73:52-62. doi:10.1016/j.jemermed.2025.01.007

2. Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19(10):1083-1087. doi:10.1016/S0196-0644(05)81508-2

3. Abdelmonem H, Abdelhay HM, Abdelwadoud GT, et al. The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. BMC Neurol. 2023;23(1):221. doi:10.1186/s12883-023-03259-7

4. Eken C. Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. Am J Emerg Med. 2015;33(3):331-337. doi:10.1016/j.ajem.2014.11.013